company background image
ICVX logo

Icosavax NasdaqGS:ICVX Stock Report

Last Price

US$15.31

Market Cap

US$777.8m

7D

-0.6%

1Y

68.8%

Updated

19 Feb, 2024

Data

Company Financials +

ICVX Stock Overview

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology.

ICVX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Icosavax, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Icosavax
Historical stock prices
Current Share PriceUS$15.31
52 Week HighUS$16.11
52 Week LowUS$4.75
Beta1.28
11 Month Change-0.78%
3 Month Change50.84%
1 Year Change68.80%
33 Year Changen/a
5 Year Changen/a
Change since IPO-56.22%

Recent News & Updates

Recent updates

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Jul 04
We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Mar 10
Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Oct 18
Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax GAAP EPS of -$0.57

Aug 15

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22
Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24
Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29
We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Shareholder Returns

ICVXUS BiotechsUS Market
7D-0.6%1.2%1.0%
1Y68.8%21.2%33.7%

Return vs Industry: ICVX exceeded the US Biotechs industry which returned 4.8% over the past year.

Return vs Market: ICVX exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is ICVX's price volatile compared to industry and market?
ICVX volatility
ICVX Average Weekly Movement15.1%
Biotechs Industry Average Movement9.7%
Market Average Movement6.3%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ICVX's share price has been volatile over the past 3 months.

Volatility Over Time: ICVX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201760Adam Simpsonicosavax.com

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.

Icosavax, Inc. Fundamentals Summary

How do Icosavax's earnings and revenue compare to its market cap?
ICVX fundamental statistics
Market capUS$777.79m
Earnings (TTM)-US$96.71m
Revenue (TTM)n/a

0.0x

P/S Ratio

-8.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ICVX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$70.04m
Gross Profit-US$70.04m
Other ExpensesUS$26.67m
Earnings-US$96.71m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.90
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ICVX perform over the long term?

See historical performance and comparison